PTCT at a glance
PTC THERAPEUTICS, INC. (PTCT, SEC CIK 1070081) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on July 30, 2026, an 8-K current report on September 21, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), PTC THERAPEUTICS, INC. (PTCT) reported revenue of $1.7 billion (up 114.5% from FY2024) and net income of $682.6 million. Diluted EPS was $7.78.
- As of June 30, 2026, 34 institutional investment managers tracked by SignalX reported holding PTC THERAPEUTICS, INC. (PTCT) shares worth $3.4 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by STEELE GLENN JR MD PHD on September 30, 2026 of 12,000 shares at $65.16 per share.
- In the last 90 days, PTCT insiders reported 0 open-market purchases ($0) and 24 open-market sales ($9.9M) on Form 4, a net sale of $9.9M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.7B
- +114.5% vs prior year
- Insiders · 90 days
- 0 buys · 24 sells
- Net −$9.9M
- 13F holders
- 34 funds
- $3.4B · +0 vs prior quarter
- Latest 8-K
- Sep 21, 2026
- Item 7.01 · Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Development and commercialization of treatments for rare diseases, with focus on sepiapterin programs from Censa acquisition
- Strategic shift: Rights Satisfaction Agreement canceled contingent net sales payments, replaced with upfront $225.1M cash payment plus up to $500M milestone payments
- Notable quantitative metric: $152.5M paid in development/regulatory milestones for sepiapterin since acquisition, including $57.5M in 2025 alone
- Financial risk detail: Stressed need for substantial additional funding; reliance on equity, debt, collaborations, with potential dilution and restrictive covenants risks
Risk Factors
- Regulatory risk U.S. FDA withdrawal of Translarna NDA resubmission for nmDMD after negative feedback in January 2026
- Geopolitical exposure Sephience marketing approvals in U.S., EEA, Japan, Brazil with $111.2M 2025 net revenues, but country-specific pricing/licensing risks
- Operational risk Emflaza U.S. orphan drug exclusivity expired Feb 2024 leading to increased generic competition impacting revenue
- Competitive risk Emflaza facing generic competition post orphan drug exclusivity expiration, negatively affecting net product revenue
- Financial risk Revenue concentration: Translarna net revenues $235.3M and Emflaza $146.4M in 2025, key products with regulatory uncertainties
Management Discussion & Analysis
- Revenue impact: upfront $1.0B from Novartis Agreement in Jan 2025, with potential $1.9B milestones, 40% US profits share, tiered double-digit royalties ex-US
- Operating cash flow $711.2M in 2025 vs $(107.7)M in 2024 and $(158.4)M in 2023, driven by Novartis upfront and clinical/commercial spend
- Investing cash flow used $862.0M in 2025, primarily for product rights acquisition, marketable securities, and fixed assets purchases
- Financing cash flow $331.1M in 2025 from Royalty Pharma fundings, option exercises, ESPP issuance, offset by contingent consideration and lease payments
- Forward risks: ongoing costs from commercialization, clinical trials, regulatory requirements; milestone and royalty payment obligations; dependence on market access and pricing; 2026 Convertible Notes interest $4.3M annually
AI summary of the PTCT 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Cash, equivalents and marketable securities $2.23B as of June 30, 2026
- Operating cash flow $70.1M vs $811.8M YoY
- Financing cash flow $218.3M vs $13.4M YoY, including $535.4M net 2031-note proceeds
- $328.8M used to repurchase $222.0M principal of 2026 Convertible Notes
- PROVE-FA open-label study planned for Q3 2026 following FDA feedback on vatiquinone NDA resubmission
Risk Factors
- New insider-trading disclosure: Director Michael Schmertzler adopted a Rule 10b5-1 sale plan on May 14, 2026
- Director trading plan: Up to 170,000 shares sale authorized through February 1, 2027
- New debt documentation: Indenture dated June 18, 2026, indicating newly issued or amended notes
- Compliance risk: Director and officer transactions must comply with insider-trading laws and the Company’s insider-trading policy
AI summary of the PTCT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- PTC completed acquisition of ST-920 from Sangamo, a BLA-stage one-time AAV gene therapy candidate for Fabry disease
- Asset-stage acquisition adds a potentially near-commercial rare-disease therapy to PTC’s pipeline
Item 8.01: Other Events
- Acquisition completed September 21, 2026, expanding PTC Therapeutics’ development portfolio
- Rolling U.S. BLA submission for ST-920 expected in fourth quarter 2026
Item EX-99.1: Item EX-99.1
- Acquisition of ST-920 from Sangamo completed, adding a BLA-stage Fabry disease gene therapy to PTC’s rare-disease portfolio
- Rolling FDA BLA submission targeting completion in Q4 2026, with accelerated approval potential
Item 1.01: Entry into a Material Definitive Agreement
- PTC to acquire ST-920, one-time AAV gene therapy candidate for Fabry disease, expanding its rare-disease pipeline
- Upfront consideration of $111 million plus up to $100 million in FDA approval milestones
Item 7.01: Regulation FD Disclosure
- PTC selected as winning bidder for ST-920, a BLA-stage one-time AAV gene therapy candidate for Fabry disease
- Acquisition from bankrupt Sangamo followed a competitive Chapter 11 auction
Item 8.01: Other Events
- Planned ST-920 acquisition: $111 million upfront plus up to $100 million FDA approval milestones
- Milestones include $80 million for accelerated approval and $20 million for traditional or full approval
Item EX-99.1: Item EX-99.1
- Winning bid to acquire ST-920, a BLA-stage Fabry gene therapy, for $111 million upfront and up to $100 million milestones
- Acquisition expected to close late Q3 or early Q4 2026, pending bankruptcy court approval, antitrust review and definitive documentation
AI summaries of PTCT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PTCT
Don't miss the next PTCT filing
- Alerts as it files. A push when PTCT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PTCT, by share count.
- Ask anything. An AI agent that reads every PTCT filing and answers with sources.
PTCT alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| STEELE GLENN JR MD PHD | M | Sep 30, 2026 | 12,000 | $11.23 |
| STEELE GLENN JR MD PHD | Sell | Sep 30, 2026 | 12,000 | $65.16 |
| STEELE GLENN JR MD PHD | M | Sep 30, 2026 | 12,000 | - |
| SCHMERTZLER MICHAEL | Sell | Sep 17, 2026 | 376 | $68.45 |
| SCHMERTZLER MICHAEL | Sell | Sep 17, 2026 | 9,624 | $67.83 |
| SCHMERTZLER MICHAEL | Sell | Sep 16, 2026 | 7,006 | $67.35 |
| SCHMERTZLER MICHAEL | Sell | Sep 16, 2026 | 2,994 | $66.58 |
| SCHMERTZLER MICHAEL | Sell | Sep 10, 2026 | 10,000 | $67.34 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $806.8M | $1.7B |
| Operating Income | - | -$302.6M | $866.9M |
| Net Income | -$626.6M | -$363.3M | $682.6M |
| Op. Margin | - | -37.5% | 50.1% |
| Net Margin | - | -45.0% | 39.4% |
| Balance Sheet | |||
| Total Assets | $1.9B | $1.7B | $2.9B |
| Equity | - | -$1.1B | -$205.3M |
| ROE | - | 33.1% | -332.5% |
| Per Share | |||
| EPS | $-8.37 | $-4.73 | $7.78 |
| Cash Flow | |||
| Operating CF | - | -$107.7M | $711.2M |
| CapEx | $28.4M | $6.5M | $8.9M |
Source: XBRL data in PTC THERAPEUTICS, INC. (PTCT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate PTCT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 34 | $3.45B |
| Q1 2026 | 34 | $2.70B |
| Q4 2025 | 31 | $2.96B |
| Q3 2025 | 31 | $2.10B |
| Q2 2025 | 29 | $1.69B |
| Q1 2025 | 25 | $1.18B |
| Q4 2024 | 22 | $887.9M |
| Q3 2024 | 18 | $352.0M |
- BlackRock+1.02M (+8%)
- T. Rowe Price Group+639.4K (+135%)
- Morgan Stanley+429.5K (+64%)
- Citadel Advisors LLC+362.6K (+94%)
- JPMorgan Chase & Co+338.0K (+98%)
- Bank of America Corp−434.6K (-23%)
- Dimensional Fund Advisors−253.0K (-28%)
- Goldman Sachs Group−209.4K (-25%)
- FMR LLC (Fidelity)−130.1K (-9%)
- Franklin Resources−94.1K (-8%)
- Millennium Management+46.5K
- Marex Group plc−9.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 224 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PTCT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 2, 2026 | - | - | - |
| 8-K | Sep 21, 2026 | - | Analysis | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 11, 2026 | - | - | - |
| 8-K | Aug 28, 2026 | - | Analysis | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 4 | Aug 6, 2026 | - | - | - |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 10-Q | Jul 30, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 16, 2026 | - | - | - |
| 4 | Jul 13, 2026 | - | - | - |
| 4 | Jul 13, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 18, 2026 | - | Analysis | - |
| 8-K | Jun 16, 2026 | - | Analysis | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
PTCT SEC filings: frequently asked questions
Are PTCT insiders buying or selling?
In the last 90 days, PTC THERAPEUTICS, INC. (PTCT) officers, directors and 10% owners reported no open-market purchases and 24 open-market sales worth $9.9 million by 7 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold PTCT stock?
As of June 30, 2026, the largest PTC THERAPEUTICS, INC. (PTCT) holders among the 13F filers tracked by SignalX were BlackRock ($1.1 billion), Vanguard Portfolio Management LLC ($402.0 million), State Street Corp ($375.1 million), Vanguard Capital Management LLC ($305.0 million), D.E. Shaw & Co ($126.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was PTCT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), PTC THERAPEUTICS, INC. (PTCT) reported revenue of $1.7 billion (up 114.5% from FY2024) and net income of $682.6 million. Diluted EPS was $7.78. The figures come from the XBRL data in the 10-K.
What are the main risks in PTCT's latest 10-K?
In the 10-K filed February 19, 2026, PTC THERAPEUTICS, INC. (PTCT) flagged: Regulatory risk U.S. FDA withdrawal of Translarna NDA resubmission for nmDMD after negative feedback in January 2026. Geopolitical exposure Sephience marketing approvals in U.S., EEA, Japan, Brazil with $111.2M 2025 net revenues, but country-specific pricing/licensing risks. (AI summary of the Risk Factors section.)
What did PTCT report in its latest 8-K?
PTC THERAPEUTICS, INC. (PTCT) filed an 8-K on September 21, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). PTC completed acquisition of ST-920 from Sangamo, a BLA-stage one-time AAV gene therapy candidate for Fabry disease.
What are the latest PTCT SEC filings?
PTC THERAPEUTICS, INC. (PTCT) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on July 30, 2026, an 8-K current report on September 21, 2026 and a Form 4 insider filing on October 2, 2026.
What is PTCT's SEC CIK number?
PTC THERAPEUTICS, INC. (PTCT)'s SEC Central Index Key (CIK) is 1070081. EDGAR lists every PTCT filing under that number.
Ask anything about PTCT
The research agent reads PTCT's filings, financials, insider trades and 13F holders, then answers with sources.